Atrás
Precio Anthera Pharmaceuticals Inc (ANTH)
Gráfico del Precio de Acciones ANTH
ANTH Ganando
Anthera Pharmaceuticals Inc
$0
0%
$0
Al cierre: Jan 16, 16:00:00 GMT-5
$0
0%
$0
Mercado Posterior: Jan 16, 20:00:00 GMT-5
Sin datos aúnEarnings FAQ
¿Cómo se comparó el EPS reciente de ANTH con las expectativas?
¿Cómo fue el desempeño de los ingresos de Anthera Pharmaceuticals Inc ANTH en el último trimestre?
¿Cuál es la estimación de ingresos para Anthera Pharmaceuticals Inc?
¿Cuál es la puntuación de calidad de ganancias de Anthera Pharmaceuticals Inc?
¿Cuándo informa Anthera Pharmaceuticals Inc sus ganancias?
¿Cuáles son las ganancias esperadas de Anthera Pharmaceuticals Inc?
¿Superó Anthera Pharmaceuticals Inc las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$0.0001
Precio de apertura
$0.0001
Rango del día
$0.0001 - $0.0001
Rango de 52 semanas
$0.0001 - $0.001
Volumen
23.8K
Volumen promedio
5.6K
EPS (TTM)
-1.63
Rendimiento de dividendos
--
Cap. de mercado
$2.6K
¿Qué es ANTH?
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Características
Estrategias de Trading
© 2025 Finture Development Limited. All rights reserved